15 results found | searching for "Dystrophy"
-
-
Understand Muscular Dystrophy, common types, diagnoses and relevant ICD-10 codes to enhance patient care & billing. https://www.outsourcestrategies.com/blog/muscular-dystrophy-updated-icd-10-codes-a-guideline-for-practitioners/
-
-
Oligonucleotide Synthesis Market to Reach $19.7 Billion by 2029: Comprehensive Analysis and Forecast https://www.marketsandmarkets.com/Market-Reports/oligonucleotide-synthesis-market-200829350.html The global oligonucleotide synthesis market is projected to reach USD 19.7 billion by 2029 from USD 8.8 billion in 2024, at a CAGR of 17.5% during the forecast period. The increased demand for oligonucleotide-based drugs like ASOs and siRNAs to treat various neurological and rare disorders such as Duchenne muscular dystrophy (DMD), spinal muscular atrophy (SMA), and hepatic veno-occlusive disease (VOD) drives market growth. Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=200829350 By product, synthesized oligonucleotides held the second-largest share of the oligonucleotide synthesis market in 2023. The demand for synthesized oligos is increasing due to growing applications of oligonucleotides in various therapeutic, research, and diagnostic applications. Oligo-based drugs is a growing market. Moreover, oligonucleotides are used as probes and primers in PCR and qPCR reactions, DNA sequencing, next-generation sequencing (NGS), fluorescent in situ hybridization (FISH), development of nucleic acid-based microarrays for pathogen detection and screening, genetic disorder identification, the study of DNA protein interactions, gene expression, gene cloning, library construction, and mutation analysis. Based on applications, the oligonucleotide synthesis market is segmented into therapeutic, research, and diagnostic applications. In 2023, the therapeutic applications segment accounted for the fastest-growing segment of the oligonucleotide synthesis market. The increasing applications of oligos as therapeutic agents (such as antisense oligos and siRNA) used in treating neurological and rare disorders are expected to drive market growth. Ongoing research to expand this therapeutic potential of oligo-based drugs to common diseases such as cardiovascular disorders will further boost the oligonucleotide therapeutic market. By end user, the pharmaceutical & biotechnology companies accounted for the second-largest share of the oligonucleotide synthesis market in 2023. The use of oligonucleotide synthesis products in drug discovery & development and biotech research is attributed to the market growth. Also, pharmaceutical & biotechnology companies are investing in research activities to develop nucleic-based therapies to combat new diseases such as cardiovascular disorders. The oligonucleotide synthesis market is divided into North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa. North America, comprising the US and Canada, is the largest regional segment in the oligonucleotide synthesis market. The large share of the North American market is due to substantial government funding for research and development of oligonucleotide-based therapies, the presence of major players in this market segment, and growing awareness about alternative medicines among the population. Europe held the second-largest share of the market globally. Growth in the European market can be attributed to factors such as the presence of a large number of academic and research institutes in the region, such as Harvard, growing investments by key market players, and increasing focus on R&D activities. Key players in the market include Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Eurofins Scientific (Luxembourg), LGC Limited (UK), Agilent Technologies, Inc. (US), Kaneka Corporation (Japan), Maravai Lifesciences Holdings, Inc. (US), Azenta, Inc. (US), Twist Bioscience Corporation (US) and Genscript Biotech Corporation (US). Prominent players in the oligonucleotide-based drugs (therapeutic applications) market are Biogen Inc. (US), Alnylam Pharmaceuticals, Inc. (US), Sarepta Therapeutics, Inc. (US), Astrazeneca (UK), Astellas Pharma Inc. (Japan), Jazz Pharmaceuticals Plc (Ireland), Nippon Shinyaku, Co. Ltd. (Japan), Ionis Pharmaceuticals, Inc. (US) and Novartis AG (Switzerland). Recent Developments of Oligonucleotide Synthesis Industry: In November 2023, LCG Biosearch Technologies, a business unit of LGC Limited, acquired PolyDesign to enhance its oligonucleotide synthesis capabilities using PolyDesign's frit technology. In October 2023, Integrated DNA Technologies (IDT), a subsidiary of Danaher Corporation, opened its therapeutic oligonucleotide manufacturing facility in Coralville, Iowa. This facility will produce reagents for cGMP cell & gene therapy, including single-guide RNAs and HDR donor oligos. -
-
According to Precision Business Insights, the Corneal Endothelial Dystrophy Market report provides an in-depth research analysis of market size, share https://www.precisionbusinessinsights.com/market-reports/corneal-endothelial-dystrophy-market -
-
Pig DNA VS Human DNA Pigs are used to study human diseases like cystic fibrosis and Duchenne muscular dystrophy. You may ask: WHY? Because the pig genome is three times closer to our genome than that of mice. Shocking, isn’t it? For example, Jung and their team (2013) have developed a porcine fibroblast model to understand obesity and metabolic syndromes in humans. Scientists have even introduced c-Myc into swine fibroblasts to generate homogenous, stable, hyaline cartilage-like cells without the formation of tumours. These swine fibroblasts will serve as a model to understand cartilage diseases. Read More:- https://kosheeka.com/swine-fibroblast-cells/ #pigcell #fibroblastcells #pigstemcells #porcinecells #pigcells #whatarefibroblastcells #whattypeofcellsarefibroblasts #pigdnavshumandna #humanandpigdnasimilarity #Cellculture #customizedprimarycells #biotechcompany #stemcells #exosomes #stemcellresearchcenter #primarycells #rengeerativemedicine #bioengineering #Kosheeka -
-
Our latest report provides a detailed analysis of the Fuchs Dystrophy Market size, growth forecast, and latest trends. It covers the market trends, growth prospects, investment opportunities, and industry prospects. The report also includes an overview of the disease, market scenario, and growth trends. It further offers competitor analysis, regional analysis, and recent advancements in the Fuchs Dystrophy Market. Read More: https://www.imarcgroup.com/fuchs-dystrophy-market
-
-
A #musculardystrophy is a group of genetic conditions that cause advanced muscle weakness and loss of muscle mass, mainly in skeletal strengths, such as those in the arms and legs. But muscular dystrophy can also distress strengths in the face, in the heart, the influences that control consciousness, and, actually, any muscle in the body. Visit us http://bit.ly/2U9uyB1 -
-
Muscular Dystrophy Types, Symptoms, Diagnosis And Treatment Muscular Dystrophy (MD) is a collection of inherited muscular degeneration diseases that damage and weaken the muscles progressively. The lack of dystrophin, a protein required for normal muscle function, is responsible for the damage. Link:- https://www.advancells.com/types-of-muscular-dystrophy-and-its-symptoms/ #BeckerMuscularDystrophy #BMD #CongenitalMuscularDystrophy #CMD #DuchenneMuscularDystrophy #DMD #LimbGirdleMuscularDystrophy #MuscularDegenerationDiseases #MuscularDystrophySymptoms #MuscularDystrophyTypes #MyotonicDystrophy -
-
Duchenne Muscular Dystrophy (DMD): A genetic disorder causing progressive muscle weakness and wasting, typically leading to life-threatening complications. https://www.knowledgedetective.com/
-
-
The adeno-associated viral vector market is anticipated to grow at a CAGR of more than 10% by 2035, claims Roots Analysis Given their low immunogenicity, diversified targets and ability to offer higher biosafety, the adeno-associated viral vectors are actively being evaluated for the development of various therapies for the treatment of chronic diseases and infections. London Roots Analysis has announced the addition of “Adeno Viral Vector Market, 2022-2035” report to its list of offerings. Owing to their unique biology, simple structure and lack of disease correlation, the adeno-associated viral vectors have garnered significant interest within the medical community. In fact, various adeno-associated viral vector-based therapies have been developed for the treatment of multiple indications, including retinitis pigmentosa, cystic fibrosis and Duchenne muscular dystrophy. As a result, the demand for such vectors have increased tremendously, thereby creating lucrative opportunities for the players engaged in the adeno-associated viral vector market. Among various gene delivery vectors available, adeno-associated viral (AAV) vectors have emerged as one of the most efficient viral vectors. Till now, the USFDA has approved two adeno-associated viral vectors based drugs, LUXTURNA® and ZOLGENSMA®. Considering the prevalent trends and projected opportunity associated with the overall adeno-associated viral vectors / AAV vector domain, we believe that the market is anticipated to witness substantial growth in the foreseen future. To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/adeno-associated-viral-vector-market/request-sample.html Key Market Insights More than 550 adeno-associated viral vector-based therapies have been / are being evaluated across different stages of development for the treatment of various disorders Close to 20% of the pipeline candidates are under clinical evaluation; majority (26%) of these candidates are being developed for the treatment of neurological disorders, followed by those being evaluated for the treatment of ophthalmic disorders (21%). More than 155 clinical trials have been registered for the evaluation of adeno-associated viral vector-based therapies, worldwide The clinical research activity, in terms of number of trials registered, is reported to have increased at a CAGR of 20%, since 2010. Of the total number of trials registered, close to 25% have already been completed, while 46% of the studies are actively recruiting participants. More than 50 start-ups have emerged in the last 10 years in the adeno-associated viral vector domain Close to 60% of the start-ups have been established in North America. Among these, more than 95% of the firms are based in the US. This is followed by Europe, accounting for more than 30% of the start-ups focused on adeno-associated viral vectors. North America is anticipated to capture larger share of the adeno-associated viral vector market by 2035 The market will be primarily driven by the manufacturers developing therapies for the treatment of oncological disorders (20%). In addition, by 2035, majority market share of the adeno-associated viral vector-based therapies is anticipated to be dominated by commercial scale of operation (46%), followed by preclinical (40%) and clinical (14%). For additional details please visit https://www.rootsanalysis.com/reports/adeno-associated-viral-vector-market.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Targeted protein degradation market, 2022-2035 2. Cell Therapy Manufacturing Market, 2021-2030 3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/
-
-
RNAI THERAPY OFFERS THE POTENTIAL TO REVOLUTIONIZE THE BIOPHARMACEUTICAL INDUSTRY Owing to their vast potential in controlling disease-associated gene expression, RNAi therapeutics have emerged as a key segment of the market; several big pharma players have undertaken RNAi focused initiatives. In addition to effective gene silencing, these candidates can be deployed for applications related to precision medicine. Studies have also demonstrated the safety of RNAi therapeutics for in systemic delivery, paving the way for systemic applications of the therapy. A number of novel and sophisticated technologies / platforms have been / are being developed to overcome the challenges associated with RNAi therapeutics, as well as further enhance their specificity and stability. Further, considering their high knockdown efficiency, high target specificity and extended silencing ability, RNAi has now been established as a powerful tool for gene silencing. It is worth highlighting, RNAi has potential applications in treating several viral infections and tumors in addition to its ability in gene function determination. However, despite the numerous benefits offered by RNAi therapies, developers often face concerns related to the stability and targeted delivery of their candidates. In order to mitigate the aforementioned challenges, several players have developed novel technologies and delivery systems to ensure target specific delivery of these molecules. To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/278/request-sample.html With four approved drugs and several therapy candidates being evaluated in late stages of clinical development, the RNAi therapeutics domain presents a significant opportunity for biopharmaceutical developers. In addition, a number of RNAi therapeutics are being developed to target rare and genetic clinical conditions, such as Alpha 1-Antitrypsin Disease, Alport Syndrome, Amyloidosis and Muscular Dystrophy (Facioscapulohumeral Muscular Dystrophy and Oculopharyngeal Muscular Dystrophy). It is also worth highlighting that over 2,100 patents have been filed / granted, highlighting the continuous pace of ongoing innovation in this field. Given the high research activity and ongoing technology advancements, the RNAi therapeutics market is poised to grow at a steady pace in the foreseen future. An insightful technology competitiveness analysis, benchmarking RNAi technologies, based on supplier power (in terms of company size and years of experience) and key technology specifications. The analysis was designed to enable stakeholder companies to compare their existing capabilities within and beyond their respective peer groups and identify opportunities to achieve a competitive edge in the industry. For additional details please visit https://www.rootsanalysis.com/reports/view_document/rnai-therapeutics-market/278.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Targeted protein degradation market, 2022-2035 2. Cell Therapy Manufacturing Market, 2021-2030 3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/
Copyright 2019 © P-tweets Refunds